TrialStem cell research & therapy2024

Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial.

Masao Koda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.